PURPOSE: To evaluate the role of the sodium bicarbonate cotransporter (NBCe1) as a component of the corneal endothelial pump in the in vivo rabbit eye. METHODS: Lentiviruses with NBCe1 shRNA and GFP expression cassettes were injected intracamerally. Knockdown efficacy was determined 1 week to 4 weeks later by immunofluorescence, Western blot analysis, and PCR. Functional effects were monitored by corneal thickness (CT) and brinzolamide sensitivity. RESULTS: Within 24 hours there was a modest anterior chamber inflammation that resolved within 48 hours. At 4 × 10(6) IFU, more than 95% of the corneal endothelial surface showed GFP fluorescence above background within 7 days. At 14 to 21 days, signs of anterior chamber inflammation reemerged, and endothelial cell GFP fluorescence disappeared within 40 days after injection. The second phase of inflammation could be avoided by using GFP-less viruses. There was no significant difference in CT between scrambled sequence and NBCe1 shRNA-injected eyes over 3 weeks. Two drops of 1% brinzolamide produced 7.85% ± 3.3% corneal swelling within 5 hours of topical instillation. However, in corneas showing more than 25% NBCe1 knockdown (30 of 42 rabbits; 59% ± 15% knockdown), corneal swelling was significantly higher (10.1% ± 2.9%) relative to control eyes. CONCLUSIONS: FIV-based lentiviral vectors can transfect CE with shRNA in rabbits. The response to GFP is consistent, with previous studies showing the production of anti-GFP antibodies. Partial knockdown of NBCe1 did not affect baseline CT, which is consistent with the corneal endothelium having a substantial functional reserve. Provocative testing using, brinzolamide, however, revealed an underlying deficiency, confirming the importance of NBCe1 bicarbonate transport and demonstrating the concerted action between NBCe1 and carbonic anhydrases.
PURPOSE: To evaluate the role of the sodium bicarbonate cotransporter (NBCe1) as a component of the corneal endothelial pump in the in vivo rabbit eye. METHODS: Lentiviruses with NBCe1 shRNA and GFP expression cassettes were injected intracamerally. Knockdown efficacy was determined 1 week to 4 weeks later by immunofluorescence, Western blot analysis, and PCR. Functional effects were monitored by corneal thickness (CT) and brinzolamide sensitivity. RESULTS: Within 24 hours there was a modest anterior chamber inflammation that resolved within 48 hours. At 4 × 10(6) IFU, more than 95% of the corneal endothelial surface showed GFP fluorescence above background within 7 days. At 14 to 21 days, signs of anterior chamber inflammation reemerged, and endothelial cell GFP fluorescence disappeared within 40 days after injection. The second phase of inflammation could be avoided by using GFP-less viruses. There was no significant difference in CT between scrambled sequence and NBCe1 shRNA-injected eyes over 3 weeks. Two drops of 1% brinzolamide produced 7.85% ± 3.3% corneal swelling within 5 hours of topical instillation. However, in corneas showing more than 25% NBCe1 knockdown (30 of 42 rabbits; 59% ± 15% knockdown), corneal swelling was significantly higher (10.1% ± 2.9%) relative to control eyes. CONCLUSIONS: FIV-based lentiviral vectors can transfect CE with shRNA in rabbits. The response to GFP is consistent, with previous studies showing the production of anti-GFP antibodies. Partial knockdown of NBCe1 did not affect baseline CT, which is consistent with the corneal endothelium having a substantial functional reserve. Provocative testing using, brinzolamide, however, revealed an underlying deficiency, confirming the importance of NBCe1 bicarbonate transport and demonstrating the concerted action between NBCe1 and carbonic anhydrases.
Authors: Román A Barraza; Carol A Rasmussen; Nils Loewen; J Douglas Cameron; B'Ann T Gabelt; Wu-Lin Teo; Paul L Kaufman; Eric M Poeschla Journal: Hum Gene Ther Date: 2009-03 Impact factor: 5.695
Authors: LaKisha K Buie; Carol A Rasmussen; Eric C Porterfield; Vinod S Ramgolam; Vivian W Choi; Silva Markovic-Plese; Richard J Samulski; Paul L Kaufman; Teresa Borrás Journal: Invest Ophthalmol Vis Sci Date: 2009-08-13 Impact factor: 4.799
Authors: A Georgiadis; M Tschernutter; J W B Bainbridge; S J Robbie; J McIntosh; A C Nathwani; A J Smith; R R Ali Journal: Gene Ther Date: 2009-12-10 Impact factor: 5.250
Authors: Daniel M Paskowitz; Kenneth P Greenberg; Douglas Yasumura; Dirk Grimm; Haidong Yang; Jacque L Duncan; Mark A Kay; Matthew M Lavail; John G Flannery; Douglas Vollrath Journal: Hum Gene Ther Date: 2007-10 Impact factor: 5.695
Authors: John M Nickerson; Shannon E Getz; Jana T Sellers; Micah A Chrenek; Penny Goodman; Christiana J Bernal; Jeffrey H Boatright Journal: Methods Mol Biol Date: 2014